Actinium Pharmaceuticals presents promising preclinical data for its combination of menin inhibitors with ARC Actimab-A in acute myeloid leukemia (AML) models.
Actinium Pharmaceuticals presents promising preclinical data for its combination of menin inhibitors with ARC Actimab-A in acute myeloid leukemia (AML) models. Menin inhibitors are being developed for AML patients with a KMT2A gene rearrangement. Actimab-A shows high response rates, MRD negativity, and improved survival in high-risk, relapsed, and refractory patients, including those with TP53 mutations and venetoclax failures.
June 17, 2024
4 Articles